<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27990776</article-id><article-id pub-id-type="pmc">5412941</article-id><article-id pub-id-type="doi">10.1111/dom.12848</article-id><article-id pub-id-type="publisher-id">DOM12848</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>Sodium&#x02010;glucose co&#x02010;transporter&#x02010;2 inhibitor use and dietary carbohydrate intake in <styled-content style="fixed-case">J</styled-content>apanese individuals with type 2 diabetes: <styled-content style="fixed-case">A</styled-content> randomized, open&#x02010;label, 3&#x02010;arm parallel comparative, exploratory study</article-title><alt-title alt-title-type="right-running-head"><styled-content style="fixed-case">YABE</styled-content><sc>et al</sc>.</alt-title><alt-title alt-title-type="left-running-head"><styled-content style="fixed-case">YABE</styled-content><sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="dom12848-cr-0001" contrib-type="author" corresp="yes"><name><surname>Yabe</surname><given-names>Daisuke</given-names></name><degrees>MD, PhD</degrees><address><email>ydaisuke-kyoto@umin.ac.jp</email></address><xref ref-type="aff" rid="dom12848-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="dom12848-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="dom12848-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="dom12848-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12848-cr-0002" contrib-type="author"><name><surname>Iwasaki</surname><given-names>Masahiro</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12848-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="dom12848-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12848-cr-0003" contrib-type="author"><name><surname>Kuwata</surname><given-names>Hitoshi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12848-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="dom12848-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12848-cr-0004" contrib-type="author"><name><surname>Haraguchi</surname><given-names>Takuya</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12848-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12848-cr-0005" contrib-type="author"><name><surname>Hamamoto</surname><given-names>Yoshiyuki</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom12848-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="dom12848-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="dom12848-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12848-cr-0006" contrib-type="author"><name><surname>Kurose</surname><given-names>Takeshi</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom12848-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="dom12848-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12848-cr-0007" contrib-type="author"><name><surname>Sumita</surname><given-names>Kiminobu</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12848-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12848-cr-0008" contrib-type="author"><name><surname>Yamazato</surname><given-names>Hitoshi</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12848-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12848-cr-0009" contrib-type="author"><name><surname>Kanada</surname><given-names>Shigeto</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12848-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12848-cr-0010" contrib-type="author" corresp="yes"><name><surname>Seino</surname><given-names>Yutaka</given-names></name><degrees>MD, PhD</degrees><address><email>seino.yutaka@e2.kepco.co.jp</email></address><xref ref-type="aff" rid="dom12848-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="dom12848-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="dom12848-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Yutaka Seino Distinguished Centre for Diabetes Research</named-content><institution>Kansai Electric Power Medical Research Institute</institution><named-content content-type="city">Kobe</named-content><country country="JP">Japan</country></aff><aff id="dom12848-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Centre for Diabetes, Endocrinology and Metabolism</named-content><institution>Kansai Electric Power Hospital</institution><named-content content-type="city">Osaka</named-content><country country="JP">Japan</country></aff><aff id="dom12848-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Centre for Metabolism and Clinical Nutrition</named-content><institution>Kansai Electric Power Hospital</institution><named-content content-type="city">Osaka</named-content><country country="JP">Japan</country></aff><aff id="dom12848-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Division of Molecular and Metabolic Medicine, Department of Physiology and Cell Biology</named-content><institution>Kobe University Graduate School of Medicine</institution><named-content content-type="city">Kobe</named-content><country country="JP">Japan</country></aff><aff id="dom12848-aff-0005"><label><sup>5</sup></label><institution>Medical Corporation Heishinkai OCROM Clinic</institution><named-content content-type="city">Osaka</named-content><country>Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> Daisuke Yabe and Yutaka Seino, Yutaka Seino Distinguished Centre for Diabetes Research, Kansai Electric Power Medical Research Institute, 1&#x02010;5&#x02010;6 Minatojimaminamimachi, Chuo&#x02010;ku, Kobe 650&#x02010;0047, Japan.Email: <email>ydaisuke-kyoto@umin.ac.jp</email>; <email>seino.yutaka@e2.kepco.co.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2017</year></pub-date><volume>19</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/dom.2017.19.issue-5</issue-id><fpage>739</fpage><lpage>743</lpage><history><date date-type="received"><day>12</day><month>10</month><year>2016</year></date><date date-type="rev-recd"><day>30</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>08</day><month>12</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-19-739.pdf"/><abstract id="dom12848-abs-0001"><p id="dom12848-para-0008">This study investigated the safety and efficacy of the sodium&#x02010;glucose co&#x02010;transporter&#x02010;2 (<styled-content style="fixed-case">SGLT2</styled-content>) inhibitor luseogliflozin with differing carbohydrate intakes in <styled-content style="fixed-case">J</styled-content>apanese individuals with type 2 diabetes (<styled-content style="fixed-case">T2D</styled-content>). Participants were randomly assigned to 3 carbohydrate&#x02010;adjusted meals for 14&#x02009;days (days 1&#x02010;14; a high carbohydrate [<styled-content style="fixed-case">HC</styled-content>; 55% total energy carbohydrate] and high glycaemic index [<styled-content style="fixed-case">HGI</styled-content>] meal; an <styled-content style="fixed-case">HC</styled-content> [55% total energy carbohydrate] and low glycaemic index [<styled-content style="fixed-case">LGI</styled-content>] meal; or a low carbohydrate [<styled-content style="fixed-case">LC</styled-content>; 40% total energy carbohydrate] and <styled-content style="fixed-case">HGI</styled-content> meal). All participants received luseogliflozin for the last 7&#x02009;days (days 8&#x02010;14), continuous glucose monitoring (<styled-content style="fixed-case">CGM</styled-content>) before and after luseogliflozin treatment (days 5&#x02010;8 and days 12&#x02010;15) and blood tests on days 1, 8 and 15. Luseogliflozin significantly decreased the area under the curve and mean of <styled-content style="fixed-case">CGM</styled-content> values in all 3 groups similarly. Fasting plasma glucose, insulin and glucagon were similar at all time points. Ketone bodies on day 15 were significantly higher in the <styled-content style="fixed-case">LC&#x02010;HGI</styled-content> group compared with the <styled-content style="fixed-case">HC&#x02010;HGI</styled-content> and <styled-content style="fixed-case">HC&#x02010;LGI</styled-content> groups. In conclusion, luseogliflozin has similar efficacy and safety in <styled-content style="fixed-case">J</styled-content>apanese people with <styled-content style="fixed-case">T2D</styled-content> when meals contain 40% to 55% total energy carbohydrate, but a strict <styled-content style="fixed-case">LC</styled-content> diet on this class of drug should be avoided to prevent <styled-content style="fixed-case">SGLT2</styled-content> inhibitor&#x02010;associated diabetic ketoacidosis.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12848-kwd-0001">carbohydrate intake</kwd><kwd id="dom12848-kwd-0002">continuous glucose monitoring</kwd><kwd id="dom12848-kwd-0003">glucose variability</kwd><kwd id="dom12848-kwd-0004">glycaemic index</kwd><kwd id="dom12848-kwd-0005">luseogliflozin</kwd><kwd id="dom12848-kwd-0006"><styled-content style="fixed-case">SGLT2</styled-content> inhibitor</kwd><kwd id="dom12848-kwd-0007">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Taisho Toyama Pharmaceutical Co., Ltd</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="1"/><word-count count="3797"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12848</meta-value></custom-meta><custom-meta><meta-name>header-id</meta-name><meta-value>dom12848-hdr-0001</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.9 mode:remove_FC converted:02.05.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom12848-cit-1001">
<string-name>
<surname>Yabe</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Iwasaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kuwata</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Haraguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hamamoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kurose</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sumita</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yamazato</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kanada</surname>
<given-names>S</given-names>
</string-name> and <string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Sodium&#x02010;glucose co&#x02010;transporter&#x02010;2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open&#x02010;label, 3&#x02010;arm parallel comparative exploratory study</article-title>. <source>Diabetes Obes Metab</source>. <year>2017</year>;<volume>19</volume>:<fpage>739</fpage>&#x02013;<lpage>743</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.12848">https://doi.org/10.1111/dom.12848</ext-link>
<pub-id pub-id-type="pmid">27990776</pub-id></mixed-citation>
</p></notes><notes><fn-group><fn id="dom12848-note-0101"><p>
<bold>Funding information</bold> This clinical trial was funded by Taisho Toyama Pharmaceutical Co., Ltd. The funder had no involvement in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></notes></front><body><sec id="dom12848-sec-0001"><label>1</label><title>INTRODUCTION</title><p id="dom12848-para-0009">Sodium&#x02010;glucose co&#x02010;transporter 2 (SGLT2) inhibitors have recently been developed as a novel class of glucose&#x02010;lowering agents for the management of type 2 diabetes (T2D).<xref rid="dom12848-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12848-bib-0002" ref-type="ref">2</xref> SGLT2 inhibitors enhance urinary glucose excretion (UGE), thereby ameliorating both pre&#x02010; and postprandial glucose excursions insulin&#x02010;independently, and also lead to substantial body weight reduction. Clinical trials have demonstrated the efficacy and safety of SGLT2 inhibitors, as a class, in people with T2D; however, there are concerns regarding severe adverse events associated with the use of SGLT2 inhibitors in real clinical settings.<xref rid="dom12848-bib-0003" ref-type="ref">3</xref> Among these, diabetic ketoacidosis (DKA) near normoglycaemia or even euglycaemic DKA in individuals receiving SGLT2 inhibitors has drawn considerable attention.<xref rid="dom12848-bib-0004" ref-type="ref">4</xref>, <xref rid="dom12848-bib-0005" ref-type="ref">5</xref>, <xref rid="dom12848-bib-0006" ref-type="ref">6</xref> SGLT2 inhibitors lower plasma glucose and circulating insulin levels through enhancement of UGE; they also enhance glucagon secretion. Reduced insulin and elevated glucagon levels stimulate lipolysis in fat and hepatic ketogenesis, which could trigger onset of euglycaemic DKA under certain conditions, such as insulin&#x02010;dependent type 1 diabetes (T1D) and T2D characterized primarily by &#x003b2;&#x02010;cell dysfunction.<xref rid="dom12848-bib-0004" ref-type="ref">4</xref>, <xref rid="dom12848-bib-0005" ref-type="ref">5</xref>, <xref rid="dom12848-bib-0006" ref-type="ref">6</xref> Recently, it was reported that a Japanese patient with T2D on a strict low&#x02010;carbohydrate diet developed euglycaemic DKA after initiation of the SGLT2 inhibitor ipraglifrozin.<xref rid="dom12848-bib-0007" ref-type="ref">7</xref> It is possible that low carbohydrate intake together with SGLT2 inhibitor usage could have limited circulating insulin levels and thereby induced euglycaemic DKA. The American Diabetes Association sets no general recommendations on the carbohydrate content of meals.<xref rid="dom12848-bib-0008" ref-type="ref">8</xref> The Japanese Diabetes Society recommends that individuals with diabetes should normally take 50% to 60% of total energy from carbohydrates (TEC),<xref rid="dom12848-bib-0009" ref-type="ref">9</xref> but indicates that &#x0003c;50% TEC may be allowed, depending on patient preference and diabetes pathophysiology. However, there has been no examination of safety and efficacy of SGLT2 inhibitors with regard to different meal compositions, especially carbohydrate content and glycaemic index (GI).</p><p id="dom12848-para-0010">In the present study, we compared the efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese people with T2D receiving meals of different carbohydrate content (55% vs 40% of TEC) and differing GIs.</p></sec><sec id="dom12848-sec-0002"><label>2</label><title>METHODS</title><sec id="dom12848-sec-0003"><label>2.1</label><title>Study protocol</title><p id="dom12848-para-0011">This was a multicentre, randomized, open&#x02010;label, 3&#x02010;arm parallel comparative study in Japanese people with T2D (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>, NCT02500186 and UMIN, UMIN000017838). Eligible participants were randomly assigned into 3 groups in a 1:1:1 ratio (Figures S1 and S2). Those participants who were taking 1 oral antidiabetic drug or a glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1) receptor agonist underwent a washout period of at least 4&#x02009;weeks before randomization. Participants in each group consumed the test meals of 1800&#x02009;kcal/d with different carbohydrate adjustment (the high carbohydrate [HC]&#x02010;high GI [HGI] group received 55% TEC and HGI meals; the HC&#x02010;low GI [LGI] group received 55% TEC and LGI meals; and the low carbohydrate [LC]&#x02010;HGI group received 40% TEC and HGI meals) for 14&#x02009;days (days 1&#x02010;14) as described in Appendix S1. Participants received oral luseogliflozin 2.5&#x02009;mg before breakfast once daily for the final 7&#x02009;days (days 8&#x02010;14). Blood sampling was conducted on days 1, 8 and 15; continuous glucose monitoring (CGM) was performed twice during the trial (days 5&#x02010;8 and days 12&#x02010;15), as described in Appendix S1. This trial was conducted in 2 medical institutions in Osaka, Japan after obtaining approval from both ethics committees. Written informed consent was obtained from all participants.</p></sec><sec id="dom12848-sec-0004"><label>2.2</label><title>Study population</title><p id="dom12848-para-0012">Eligible participants were aged 20 to 64&#x02009;years, had a treatment history of a single oral hypoglycaemic agent or GLP&#x02010;1 receptor agonist with glycated haemoglobin (HbA1c) concentration &#x02264;10.0% (&#x02264;86&#x02009;mmol/mol) or no drug treatment with HbA1c concentration 7.0% to 10.0% (53&#x02010;86&#x02009;mmol/mol) and body mass index (BMI) &#x02265;20 and &#x0003c;30&#x02009;kg/m<sup>2</sup>. Participants with T1D, renal impairment with estimated glomerular filtration rate &#x0003c;45&#x02009;mL/min/1.73&#x02009;m<sup>2</sup>, liver disease, cardiac disease, serious gastrointestinal tract disease, history of gastrointestinal surgery, alcohol abuse, malignancy, or pregnancy were excluded. The sample size was determined with reference to a recent clinical trial of luseogliflozin.<xref rid="dom12848-bib-0010" ref-type="ref">10</xref>
</p></sec><sec id="dom12848-sec-0005"><label>2.3</label><title>Study assessments</title><p id="dom12848-para-0013">The primary endpoints were mean, SD, area under the curve (AUC) of glucose levels, and mean amplitude of glycaemic excursions (MAGE) derived from CGM data.<xref rid="dom12848-bib-0011" ref-type="ref">11</xref> Other endpoints included fasting plasma glucose (FPG), insulin, C&#x02010;peptide, glucagon, ketone bodies and non&#x02010;esterified fatty acids. These endpoints were assessed in the full analysis set population (ie, participants who received at least 1 dose of luseoglifrozin with at least 1 point of efficacy data available). Adverse events, using system organ class/preferred terms, and adverse drug reactions were summarized for the safety analysis set population (ie, participants who received at least 1 dose of luseoglifrozin with at least 1 point of safety data available).</p></sec><sec id="dom12848-sec-0006"><label>2.4</label><title>Statistical analysis</title><p id="dom12848-para-0014">All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina). Baseline characteristics were compared using analysis of variance; a significance level of 15% (2&#x02010;sided) was used to examine the heterogeneity of participant characteristics. Repeated measures were assessed using mixed&#x02010;design analysis of covariance. The unrestricted least significant difference method was applied to calculate the least squares mean and 95% confidence interval for changes in efficacy variables. Statistical significance was determined at the 5% level.</p></sec></sec><sec id="dom12848-sec-0007"><label>3</label><title>RESULTS</title><p id="dom12848-para-0015">Twenty&#x02010;four Japanese people with T2D were recruited and randomly assigned into 3 groups: HC&#x02010;HGI, HC&#x02010;LGI and LC&#x02010;HGI (Figure S1). These groups had similar baseline data (Table <xref rid="dom12848-tbl-0001" ref-type="table-wrap">1</xref>), the duration of T2D in the LC&#x02010;HGI group being slightly longer than in the HC&#x02010;HGI and HC&#x02010;LGI groups, but the difference was non&#x02010;significant statistically.</p><table-wrap id="dom12848-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic data of participants in full analysis set</p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"/><col width="1*" align="char" char="( &#x000b1;" span="1"/><col width="1*" align="char" char="( &#x000b1;" span="1"/><col width="1*" align="char" char="( &#x000b1;" span="1"/><col width="1*" align="char" char="." span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th id="dom12848-ent-0001" align="left" valign="bottom" rowspan="1" colspan="1"/><th id="dom12848-ent-0002" align="char" valign="bottom" rowspan="1" colspan="1">HC&#x02010;HGI group</th><th id="dom12848-ent-0003" align="char" valign="bottom" rowspan="1" colspan="1">HC&#x02010;LGI group</th><th id="dom12848-ent-0004" align="char" valign="bottom" rowspan="1" colspan="1">LC&#x02010;HGI group</th><th id="dom12848-ent-0005" align="char" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody valign="top"><tr><td id="dom12848-ent-0006" align="left" valign="top" rowspan="1" colspan="1">Number of participants (men, women)</td><td id="dom12848-ent-0007" align="char" valign="top" rowspan="1" colspan="1">8 (5, 3)</td><td id="dom12848-ent-0008" align="char" valign="top" rowspan="1" colspan="1">8 (6, 2)</td><td id="dom12848-ent-0009" align="char" valign="top" rowspan="1" colspan="1">7 (7, 0)</td><td id="dom12848-ent-0010" align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="dom12848-ent-0011" align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td id="dom12848-ent-0012" align="char" valign="top" rowspan="1" colspan="1">54.3&#x02009;&#x000b1;&#x02009;5.2</td><td id="dom12848-ent-0013" align="char" valign="top" rowspan="1" colspan="1">55.0&#x02009;&#x000b1;&#x02009;5.0</td><td id="dom12848-ent-0014" align="char" valign="top" rowspan="1" colspan="1">56.9&#x02009;&#x000b1;&#x02009;7.3</td><td char="." id="dom12848-ent-0015" align="char" valign="top" rowspan="1" colspan="1">.6838</td></tr><tr><td id="dom12848-ent-0016" align="left" valign="top" rowspan="1" colspan="1">Duration of type 2 diabetes, years</td><td id="dom12848-ent-0017" align="char" valign="top" rowspan="1" colspan="1">4.4&#x02009;&#x000b1;&#x02009;3.3</td><td id="dom12848-ent-0018" align="char" valign="top" rowspan="1" colspan="1">4.5&#x02009;&#x000b1;&#x02009;3.5</td><td id="dom12848-ent-0019" align="char" valign="top" rowspan="1" colspan="1">7.6&#x02009;&#x000b1;&#x02009;4.3</td><td char="." id="dom12848-ent-0020" align="char" valign="top" rowspan="1" colspan="1">.1993</td></tr><tr><td id="dom12848-ent-0021" align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td id="dom12848-ent-0022" align="char" valign="top" rowspan="1" colspan="1">24.31&#x02009;&#x000b1;&#x02009;2.04</td><td id="dom12848-ent-0023" align="char" valign="top" rowspan="1" colspan="1">24.50&#x02009;&#x000b1;&#x02009;2.74</td><td id="dom12848-ent-0024" align="char" valign="top" rowspan="1" colspan="1">26.03&#x02009;&#x000b1;&#x02009;2.66</td><td char="." id="dom12848-ent-0025" align="char" valign="top" rowspan="1" colspan="1">.3709</td></tr><tr><td id="dom12848-ent-0026" align="left" valign="top" rowspan="1" colspan="1">Systolic blood pressure, mm Hg</td><td id="dom12848-ent-0027" align="char" valign="top" rowspan="1" colspan="1">119.9&#x02009;&#x000b1;&#x02009;14.0</td><td id="dom12848-ent-0028" align="char" valign="top" rowspan="1" colspan="1">123.3&#x02009;&#x000b1;&#x02009;17.8</td><td id="dom12848-ent-0029" align="char" valign="top" rowspan="1" colspan="1">118.3&#x02009;&#x000b1;&#x02009;9.9</td><td char="." id="dom12848-ent-0030" align="char" valign="top" rowspan="1" colspan="1">.7939</td></tr><tr><td id="dom12848-ent-0031" align="left" valign="top" rowspan="1" colspan="1">Diastolic blood pressure, mm Hg</td><td id="dom12848-ent-0032" align="char" valign="top" rowspan="1" colspan="1">73.0&#x02009;&#x000b1;&#x02009;12.4</td><td id="dom12848-ent-0033" align="char" valign="top" rowspan="1" colspan="1">76.4&#x02009;&#x000b1;&#x02009;8.1</td><td id="dom12848-ent-0034" align="char" valign="top" rowspan="1" colspan="1">73.9&#x02009;&#x000b1;&#x02009;5.0</td><td char="." id="dom12848-ent-0035" align="char" valign="top" rowspan="1" colspan="1">.7506</td></tr><tr><td id="dom12848-ent-0036" align="left" valign="top" rowspan="1" colspan="1">HbA1c, %</td><td id="dom12848-ent-0037" align="char" valign="top" rowspan="1" colspan="1">7.56&#x02009;&#x000b1;&#x02009;1.16</td><td id="dom12848-ent-0038" align="char" valign="top" rowspan="1" colspan="1">7.39&#x02009;&#x000b1;&#x02009;0.85</td><td id="dom12848-ent-0039" align="char" valign="top" rowspan="1" colspan="1">7.57&#x02009;&#x000b1;&#x02009;0.66</td><td char="." id="dom12848-ent-0040" align="char" valign="top" rowspan="1" colspan="1">.9069</td></tr><tr><td id="dom12848-ent-0041" align="left" valign="top" rowspan="1" colspan="1">FPG, mmol/L</td><td id="dom12848-ent-0042" align="char" valign="top" rowspan="1" colspan="1">7.95&#x02009;&#x000b1;&#x02009;2.33</td><td id="dom12848-ent-0043" align="char" valign="top" rowspan="1" colspan="1">8.68&#x02009;&#x000b1;&#x02009;2.37</td><td id="dom12848-ent-0044" align="char" valign="top" rowspan="1" colspan="1">8.63&#x02009;&#x000b1;&#x02009;1.30</td><td char="." id="dom12848-ent-0045" align="char" valign="top" rowspan="1" colspan="1">.7465</td></tr><tr><td id="dom12848-ent-0046" align="left" valign="top" rowspan="1" colspan="1">Fasting insulin, pmol/L</td><td id="dom12848-ent-0047" align="char" valign="top" rowspan="1" colspan="1">55.6&#x02009;&#x000b1;&#x02009;45.1</td><td id="dom12848-ent-0048" align="char" valign="top" rowspan="1" colspan="1">55.6&#x02009;&#x000b1;&#x02009;22.9</td><td id="dom12848-ent-0049" align="char" valign="top" rowspan="1" colspan="1">57.6&#x02009;&#x000b1;&#x02009;16.7</td><td char="." id="dom12848-ent-0050" align="char" valign="top" rowspan="1" colspan="1">.9902</td></tr><tr><td id="dom12848-ent-0051" align="left" valign="top" rowspan="1" colspan="1">Fasting glucagon, ng/L</td><td id="dom12848-ent-0052" align="char" valign="top" rowspan="1" colspan="1">185.9&#x02009;&#x000b1;&#x02009;52.7</td><td id="dom12848-ent-0053" align="char" valign="top" rowspan="1" colspan="1">160.3&#x02009;&#x000b1;&#x02009;30.2</td><td id="dom12848-ent-0054" align="char" valign="top" rowspan="1" colspan="1">161.6&#x02009;&#x000b1;&#x02009;22.9</td><td char="." id="dom12848-ent-0055" align="char" valign="top" rowspan="1" colspan="1">.3430</td></tr><tr><td id="dom12848-ent-0056" align="left" valign="top" rowspan="1" colspan="1">SUIT</td><td id="dom12848-ent-0057" align="char" valign="top" rowspan="1" colspan="1">27.49&#x02009;&#x000b1;&#x02009;9.45</td><td id="dom12848-ent-0058" align="char" valign="top" rowspan="1" colspan="1">28.22&#x02009;&#x000b1;&#x02009;15.33</td><td id="dom12848-ent-0059" align="char" valign="top" rowspan="1" colspan="1">26.53&#x02009;&#x000b1;&#x02009;7.55</td><td char="." id="dom12848-ent-0060" align="char" valign="top" rowspan="1" colspan="1">.9601</td></tr><tr><td id="dom12848-ent-0061" align="left" valign="top" rowspan="1" colspan="1">HOMA&#x02010;IR</td><td id="dom12848-ent-0062" align="char" valign="top" rowspan="1" colspan="1">3.2&#x02009;&#x000b1;&#x02009;3.2</td><td id="dom12848-ent-0063" align="char" valign="top" rowspan="1" colspan="1">2.9&#x02009;&#x000b1;&#x02009;1.0</td><td id="dom12848-ent-0064" align="char" valign="top" rowspan="1" colspan="1">3.2&#x02009;&#x000b1;&#x02009;1.1</td><td char="." id="dom12848-ent-0065" align="char" valign="top" rowspan="1" colspan="1">.9453</td></tr><tr><td id="dom12848-ent-0066" align="left" valign="top" rowspan="1" colspan="1">HOMA&#x02010;&#x003b2;</td><td id="dom12848-ent-0067" align="char" valign="top" rowspan="1" colspan="1">35.5&#x02009;&#x000b1;&#x02009;20.2</td><td id="dom12848-ent-0068" align="char" valign="top" rowspan="1" colspan="1">38.8&#x02009;&#x000b1;&#x02009;23.8</td><td id="dom12848-ent-0069" align="char" valign="top" rowspan="1" colspan="1">34.3&#x02009;&#x000b1;&#x02009;12.3</td><td char="." id="dom12848-ent-0070" align="char" valign="top" rowspan="1" colspan="1">.8982</td></tr><tr><td id="dom12848-ent-0071" align="left" valign="top" rowspan="1" colspan="1">Total cholesterol, mmol/L</td><td id="dom12848-ent-0072" align="char" valign="top" rowspan="1" colspan="1">5.8&#x02009;&#x000b1;&#x02009;1.2</td><td id="dom12848-ent-0073" align="char" valign="top" rowspan="1" colspan="1">4.9&#x02009;&#x000b1;&#x02009;0.6</td><td id="dom12848-ent-0074" align="char" valign="top" rowspan="1" colspan="1">5.5&#x02009;&#x000b1;&#x02009;0.8</td><td char="." id="dom12848-ent-0075" align="char" valign="top" rowspan="1" colspan="1">.2148</td></tr><tr><td id="dom12848-ent-0076" align="left" valign="top" rowspan="1" colspan="1">HDL cholesterol, mmol/L</td><td id="dom12848-ent-0077" align="char" valign="top" rowspan="1" colspan="1">1.6&#x02009;&#x000b1;&#x02009;0.5</td><td id="dom12848-ent-0078" align="char" valign="top" rowspan="1" colspan="1">1.8&#x02009;&#x000b1;&#x02009;0.3</td><td id="dom12848-ent-0079" align="char" valign="top" rowspan="1" colspan="1">1.2&#x02009;&#x000b1;&#x02009;0.2</td><td char="." id="dom12848-ent-0080" align="char" valign="top" rowspan="1" colspan="1">.1702</td></tr><tr><td id="dom12848-ent-0081" align="left" valign="top" rowspan="1" colspan="1">Triglycerides, mmol/L</td><td id="dom12848-ent-0082" align="char" valign="top" rowspan="1" colspan="1">1.3&#x02009;&#x000b1;&#x02009;1.0</td><td id="dom12848-ent-0083" align="char" valign="top" rowspan="1" colspan="1">1.8&#x02009;&#x000b1;&#x02009;0.7</td><td id="dom12848-ent-0084" align="char" valign="top" rowspan="1" colspan="1">1.7&#x02009;&#x000b1;&#x02009;0.7</td><td char="." id="dom12848-ent-0085" align="char" valign="top" rowspan="1" colspan="1">.4039</td></tr><tr><td id="dom12848-ent-0086" align="left" valign="top" rowspan="1" colspan="1">Estimated glomerular filtration rate, mL/min/1.73&#x02009;m<sup>3</sup>
</td><td id="dom12848-ent-0087" align="char" valign="top" rowspan="1" colspan="1">86.31&#x02009;&#x000b1;&#x02009;23.07</td><td id="dom12848-ent-0088" align="char" valign="top" rowspan="1" colspan="1">87.25&#x02009;&#x000b1;&#x02009;13.91</td><td id="dom12848-ent-0089" align="char" valign="top" rowspan="1" colspan="1">82.05&#x02009;&#x000b1;&#x02009;17.36</td><td char="." id="dom12848-ent-0090" align="char" valign="top" rowspan="1" colspan="1">.8506</td></tr></tbody></table><table-wrap-foot><fn id="dom12848-note-0003"><p>Values are mean&#x02009;&#x000b1;&#x02009;<styled-content style="fixed-case">SD</styled-content> or n (%). Each item was compared among the 3 groups using analysis of variance. A significance of <styled-content style="fixed-case"><styled-content style="italic-in-any-context">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.15 (2&#x02010;sided) was taken to indicate heterogeneity among the study groups.</p></fn><fn id="dom12848-note-0004"><p>Abbreviations: <styled-content style="fixed-case">HOMA&#x02010;&#x003b2;</styled-content>, homeostatic model assessment of &#x003b2;&#x02010;cell function; <styled-content style="fixed-case">HOMA&#x02010;IR</styled-content>, homeostatic model assessment of insulin resistance; <styled-content style="fixed-case">SUIT</styled-content>, secretory unit of islet in transplantation.</p></fn></table-wrap-foot></table-wrap><p id="dom12848-para-0016">Postprandial CGM values in the HC&#x02010;HGI group were consistently higher than in the HC&#x02010;LGI and LC&#x02010;HGI groups before and after initiation of luseogliflozin treatment (Figure S3). The HC&#x02010;HGI group had higher peak blood glucose level (BG<sub>max</sub>), AUC over 48&#x02009;hours (AUC<sub>0&#x02010;48h</sub>), and AUC<sub>0&#x02010;48h</sub> for glucose levels &#x0003e;10.0&#x02009;mmol/L (high&#x02010;range AUC<sub>0&#x02010;48h</sub>); mean, SD and MAGE values were higher than in the HC&#x02010;LGI and LC&#x02010;HGI groups (Table <xref rid="dom12848-tbl-0002" ref-type="table-wrap">2</xref>), although the differences were not statistically significant. Importantly, luseogliflozin treatment significantly decreased the AUC and the mean of CGM data in all 3 groups. In the LC&#x02010;HGI group, lower peak blood glucose level (BG<sub>min</sub>) and area over the curve over 48&#x02009;hour (AOC<sub>0&#x02010;48h</sub>) for glucose levels &#x0003c;3.9 mmol/L (low&#x02010;range AOC<sub>0&#x02010;48h</sub>) post&#x02010;dose were significantly different from pre&#x02010;dose, possibly because of a single participant who had extremely low blood glucose levels at night. The participant was not excluded from the analysis set because the low level of glucose was possibly attributable to CGM sensor problems.</p><table-wrap id="dom12848-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Parameters derived from continuous glucose monitoring values</p></caption><table frame="hsides" rules="groups"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" id="dom12848-ent-0091" valign="bottom" colspan="1">
</th><th colspan="3" align="left" id="dom12848-ent-0092" valign="bottom" rowspan="1">HC&#x02010;HGI</th><th colspan="3" align="left" id="dom12848-ent-0093" valign="bottom" rowspan="1">HC&#x02010;LGI</th><th colspan="3" align="left" id="dom12848-ent-0094" valign="bottom" rowspan="1">LC&#x02010;HGI</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" id="dom12848-ent-0095" valign="bottom" rowspan="1" colspan="1">&#x02212; Luseo</th><th align="center" id="dom12848-ent-0096" valign="bottom" rowspan="1" colspan="1">+ Luseo</th><th align="center" id="dom12848-ent-0097" valign="bottom" rowspan="1" colspan="1">Difference</th><th align="center" id="dom12848-ent-0098" valign="bottom" rowspan="1" colspan="1">&#x02212; Luseo</th><th align="center" id="dom12848-ent-0099" valign="bottom" rowspan="1" colspan="1">+ Luseo</th><th align="center" id="dom12848-ent-0100" valign="bottom" rowspan="1" colspan="1">Difference</th><th align="center" id="dom12848-ent-0101" valign="bottom" rowspan="1" colspan="1">&#x02212; Luseo</th><th align="center" id="dom12848-ent-0102" valign="bottom" rowspan="1" colspan="1">+ Luseo</th><th align="center" id="dom12848-ent-0103" valign="bottom" rowspan="1" colspan="1">Difference</th></tr></thead><tbody valign="top"><tr><td align="left" id="dom12848-ent-0104" valign="top" rowspan="1" colspan="1">BG<sub>max</sub>, (mmol/L)</td><td align="char" char="." id="dom12848-ent-0105" valign="top" rowspan="1" colspan="1">13.17</td><td align="char" char="." id="dom12848-ent-0106" valign="top" rowspan="1" colspan="1">12.13</td><td align="char" char="." id="dom12848-ent-0107" valign="top" rowspan="1" colspan="1">&#x02212;1.05</td><td align="char" char="." id="dom12848-ent-0108" valign="top" rowspan="1" colspan="1">12.47</td><td align="char" char="." id="dom12848-ent-0109" valign="top" rowspan="1" colspan="1">11.16</td><td align="char" char="." id="dom12848-ent-0110" valign="top" rowspan="1" colspan="1">&#x02212;1.31</td><td align="char" char="." id="dom12848-ent-0111" valign="top" rowspan="1" colspan="1">11.35</td><td align="char" char="." id="dom12848-ent-0112" valign="top" rowspan="1" colspan="1">10.29</td><td align="char" char="." id="dom12848-ent-0113" valign="top" rowspan="1" colspan="1">&#x02212;1.06</td></tr><tr><td align="left" id="dom12848-ent-0114" valign="top" rowspan="1" colspan="1">BG<sub>min</sub>, (mmol/L)</td><td align="char" char="." id="dom12848-ent-0115" valign="top" rowspan="1" colspan="1">4.56</td><td align="char" char="." id="dom12848-ent-0116" valign="top" rowspan="1" colspan="1">4.27</td><td align="char" char="." id="dom12848-ent-0117" valign="top" rowspan="1" colspan="1">&#x02212;0.29</td><td align="char" char="." id="dom12848-ent-0118" valign="top" rowspan="1" colspan="1">4.59</td><td align="char" char="." id="dom12848-ent-0119" valign="top" rowspan="1" colspan="1">4.09</td><td align="char" char="." id="dom12848-ent-0120" valign="top" rowspan="1" colspan="1">&#x02212;0.50</td><td align="char" char="." id="dom12848-ent-0121" valign="top" rowspan="1" colspan="1">4.76</td><td align="char" char="." id="dom12848-ent-0122" valign="top" rowspan="1" colspan="1">3.79<xref ref-type="fn" rid="dom12848-note-0005a">*</xref>
</td><td align="char" char="." id="dom12848-ent-0123" valign="top" rowspan="1" colspan="1">&#x02212;0.97</td></tr><tr><td align="left" id="dom12848-ent-0124" valign="top" rowspan="1" colspan="1">AUC<sub>0&#x02212;48h</sub>, (mmol&#x000b7;h/L)</td><td align="char" char="." id="dom12848-ent-0125" valign="top" rowspan="1" colspan="1">380.52</td><td align="char" char="." id="dom12848-ent-0126" valign="top" rowspan="1" colspan="1">340.06</td><td align="char" char="." id="dom12848-ent-0127" valign="top" rowspan="1" colspan="1">&#x02212;40.46</td><td align="char" char="." id="dom12848-ent-0128" valign="top" rowspan="1" colspan="1">345.90</td><td align="char" char="." id="dom12848-ent-0129" valign="top" rowspan="1" colspan="1">306.74</td><td align="char" char="." id="dom12848-ent-0130" valign="top" rowspan="1" colspan="1">&#x02212;39.16</td><td align="char" char="." id="dom12848-ent-0131" valign="top" rowspan="1" colspan="1">347.08</td><td align="char" char="." id="dom12848-ent-0132" valign="top" rowspan="1" colspan="1">296.69<xref ref-type="fn" rid="dom12848-note-0005a">*</xref>
</td><td align="char" char="." id="dom12848-ent-0133" valign="top" rowspan="1" colspan="1">&#x02212;50.39</td></tr><tr><td align="left" id="dom12848-ent-0134" valign="top" rowspan="1" colspan="1">High&#x02212;range AUC<sub>0&#x02212;48h</sub>, (mmol&#x000b7;h/L)</td><td align="char" char="." id="dom12848-ent-0135" valign="top" rowspan="1" colspan="1">20.30</td><td align="char" char="." id="dom12848-ent-0136" valign="top" rowspan="1" colspan="1">10.57<xref ref-type="fn" rid="dom12848-note-0005a">*</xref>
</td><td align="char" char="." id="dom12848-ent-0137" valign="top" rowspan="1" colspan="1">&#x02212;9.73</td><td align="char" char="." id="dom12848-ent-0138" valign="top" rowspan="1" colspan="1">8.79</td><td align="char" char="." id="dom12848-ent-0139" valign="top" rowspan="1" colspan="1">2.88<xref ref-type="fn" rid="dom12848-note-0005a">*</xref>
</td><td align="char" char="." id="dom12848-ent-0140" valign="top" rowspan="1" colspan="1">&#x02212;5.91</td><td align="char" char="." id="dom12848-ent-0141" valign="top" rowspan="1" colspan="1">3.89</td><td align="char" char="." id="dom12848-ent-0142" valign="top" rowspan="1" colspan="1">0.56</td><td align="char" char="." id="dom12848-ent-0143" valign="top" rowspan="1" colspan="1">&#x02212;3.33</td></tr><tr><td align="left" id="dom12848-ent-0144" valign="top" rowspan="1" colspan="1">Low&#x02212;range AOC<sub>0&#x02212;48h</sub>, (mmol&#x000b7;h/L)</td><td align="char" char="." id="dom12848-ent-0145" valign="top" rowspan="1" colspan="1">0.19</td><td align="char" char="." id="dom12848-ent-0146" valign="top" rowspan="1" colspan="1">0.53<xref ref-type="fn" rid="dom12848-note-0005a">*</xref>
</td><td align="char" char="." id="dom12848-ent-0147" valign="top" rowspan="1" colspan="1">0.34</td><td align="char" char="." id="dom12848-ent-0148" valign="top" rowspan="1" colspan="1">0.10</td><td align="char" char="." id="dom12848-ent-0149" valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." id="dom12848-ent-0150" valign="top" rowspan="1" colspan="1">&#x02212;0.02</td><td align="char" char="." id="dom12848-ent-0151" valign="top" rowspan="1" colspan="1">0.00</td><td align="char" char="." id="dom12848-ent-0152" valign="top" rowspan="1" colspan="1">1.50<xref ref-type="fn" rid="dom12848-note-0005a">*</xref>
</td><td align="char" char="." id="dom12848-ent-0153" valign="top" rowspan="1" colspan="1">1.50</td></tr><tr><td align="left" id="dom12848-ent-0154" valign="top" rowspan="1" colspan="1">Mean (mmol/L)</td><td align="char" char="." id="dom12848-ent-0155" valign="top" rowspan="1" colspan="1">7.94</td><td align="char" char="." id="dom12848-ent-0156" valign="top" rowspan="1" colspan="1">7.09</td><td align="char" char="." id="dom12848-ent-0157" valign="top" rowspan="1" colspan="1">&#x02212;0.85</td><td align="char" char="." id="dom12848-ent-0158" valign="top" rowspan="1" colspan="1">7.22</td><td align="char" char="." id="dom12848-ent-0159" valign="top" rowspan="1" colspan="1">6.40</td><td align="char" char="." id="dom12848-ent-0160" valign="top" rowspan="1" colspan="1">&#x02212;0.82</td><td align="char" char="." id="dom12848-ent-0161" valign="top" rowspan="1" colspan="1">7.24</td><td align="char" char="." id="dom12848-ent-0162" valign="top" rowspan="1" colspan="1">6.19<xref ref-type="fn" rid="dom12848-note-0005a">*</xref>
</td><td align="char" char="." id="dom12848-ent-0163" valign="top" rowspan="1" colspan="1">&#x02212;1.05</td></tr><tr><td align="left" id="dom12848-ent-0164" valign="top" rowspan="1" colspan="1">SD (mmol/L)</td><td align="char" char="." id="dom12848-ent-0165" valign="top" rowspan="1" colspan="1">2.20</td><td align="char" char="." id="dom12848-ent-0166" valign="top" rowspan="1" colspan="1">1.96<xref ref-type="fn" rid="dom12848-note-0005a">*</xref>
</td><td align="char" char="." id="dom12848-ent-0167" valign="top" rowspan="1" colspan="1">&#x02212;0.24</td><td align="char" char="." id="dom12848-ent-0168" valign="top" rowspan="1" colspan="1">1.77</td><td align="char" char="." id="dom12848-ent-0169" valign="top" rowspan="1" colspan="1">1.70<xref ref-type="fn" rid="dom12848-note-0005a">*</xref>
</td><td align="char" char="." id="dom12848-ent-0170" valign="top" rowspan="1" colspan="1">&#x02212;0.08</td><td align="char" char="." id="dom12848-ent-0171" valign="top" rowspan="1" colspan="1">1.54</td><td align="char" char="." id="dom12848-ent-0172" valign="top" rowspan="1" colspan="1">1.53</td><td align="char" char="." id="dom12848-ent-0173" valign="top" rowspan="1" colspan="1">&#x02212;0.01</td></tr><tr><td align="left" id="dom12848-ent-0174" valign="top" rowspan="1" colspan="1">MAGE, (mmol/L)</td><td align="char" char="." id="dom12848-ent-0175" valign="top" rowspan="1" colspan="1">5.28</td><td align="char" char="." id="dom12848-ent-0176" valign="top" rowspan="1" colspan="1">5.10</td><td align="char" char="." id="dom12848-ent-0177" valign="top" rowspan="1" colspan="1">&#x02212;0.18</td><td align="char" char="." id="dom12848-ent-0178" valign="top" rowspan="1" colspan="1">4.71</td><td align="char" char="." id="dom12848-ent-0179" valign="top" rowspan="1" colspan="1">4.53</td><td align="char" char="." id="dom12848-ent-0180" valign="top" rowspan="1" colspan="1">&#x02212;0.18</td><td align="char" char="." id="dom12848-ent-0181" valign="top" rowspan="1" colspan="1">4.18</td><td align="char" char="." id="dom12848-ent-0182" valign="top" rowspan="1" colspan="1">3.87</td><td align="char" char="." id="dom12848-ent-0183" valign="top" rowspan="1" colspan="1">&#x02212;0.31</td></tr><tr><td align="left" id="dom12848-ent-0184" valign="top" rowspan="1" colspan="1">MODD, (mmol/L)</td><td align="char" char="." id="dom12848-ent-0185" valign="top" rowspan="1" colspan="1">1.28</td><td align="char" char="." id="dom12848-ent-0186" valign="top" rowspan="1" colspan="1">1.14</td><td align="char" char="." id="dom12848-ent-0187" valign="top" rowspan="1" colspan="1">&#x02212;0.14</td><td align="char" char="." id="dom12848-ent-0188" valign="top" rowspan="1" colspan="1">1.21</td><td align="char" char="." id="dom12848-ent-0189" valign="top" rowspan="1" colspan="1">1.22</td><td align="char" char="." id="dom12848-ent-0190" valign="top" rowspan="1" colspan="1">0.01</td><td align="char" char="." id="dom12848-ent-0191" valign="top" rowspan="1" colspan="1">0.91</td><td align="char" char="." id="dom12848-ent-0192" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" char="." id="dom12848-ent-0193" valign="top" rowspan="1" colspan="1">0.09</td></tr></tbody></table><table-wrap-foot><fn id="dom12848-note-0005"><p>Minimum mean&#x02212;square values and the differences of minimum mean&#x02212;square values of Days 6&#x02212;7 (&#x02212; Luseo) and Days 13&#x02212;14 (+ Luseo) were calculated.</p></fn><fn id="dom12848-note-0005a"><label>*</label><p>&#x02009;Indicates <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 versus &#x02212; Luseo.</p></fn><fn id="dom12848-note-0005b"><p>Abbreviations: BG<sub>max</sub>, peak blood glucose level; AUC0&#x02212;48h, area under the curve over 48 h; high&#x02212;range AUC<sub>0&#x02212;48h</sub>, AUC<sub>0&#x02212;48h</sub> for glucose levels &#x02265; 181 mg/dL; (low&#x02212;range AOC<sub>0&#x02212;48h</sub>, area over the curve over 48 h for glucose levels&#x02009;&#x0003c; 70&#x02009;mg/dL; HC&#x02212;HGI, high carbohydrate&#x02212;high glycemic index; HC&#x02212;LGI, high carbohydrate&#x02212;low glycemic index; SD, standard deviation of the mean glucose concentration; LC&#x02212;HGI, low carbohydrate&#x02212;high glycemic index; MAGE, mean amplitude of glycemic excursions; MODD, mean of the daily difference.</p></fn></table-wrap-foot></table-wrap><p id="dom12848-para-0017">The FPG values on days 1, 8 and 15 did not differ among the 3 groups (Figure S4), while FPG values on days 8 and 15 were lower than on day 1 in the HC&#x02010;LGI and LC&#x02010;HGI groups and, on day 15, were lower than on day 1 in the HC&#x02010;HGI group. Insulin and C&#x02010;peptide levels on days 1, 8 and 15 did not differ among the 3 groups, while insulin and C&#x02010;peptide levels on day 15 were significantly lower than on day 1 in all 3 groups. Insulin and C&#x02010;peptide levels on day 15 were reduced, possibly as a result of FPG reduction by combined action of test meals and luseogliflozin because secretory unit of islet in transplantation and homeostatic model assessment of &#x003b2;&#x02010;cell function (Figure S5) did not change between days 1 and 15. Glucagon on days 1, 8 and 15 did not differ among the 3 groups, while glucagon levels on day 8 and day 15 were lower than on day 1 in all 3 groups, with statistical significance only in the HC&#x02010;HGI and HC&#x02010;LGI groups. Unlike previous reports,<xref rid="dom12848-bib-0012" ref-type="ref">12</xref>, <xref rid="dom12848-bib-0013" ref-type="ref">13</xref> no glucagon elevation was observed in response to luseogliflozin administration.</p><p id="dom12848-para-0018">Ketone bodies on days 1 and 8 did not differ among the 3 groups (day 1: HC&#x02010;HGI 139.1&#x02009;&#x000b1;&#x02009;193.3&#x02009;&#x000b5;mol/L; HC&#x02010;LGI 65.1&#x02009;&#x000b1;&#x02009;41.1&#x02009;&#x000b5;mol/L and LC&#x02010;HGI 115.3&#x02009;&#x000b1;&#x02009;158.2&#x02009;&#x000b5;mol/L; day 8: HC&#x02010;HGI 183.8&#x02009;&#x000b1;&#x02009;155.4&#x02009;&#x000b5;mol/L, HC&#x02010;LGI 196.5&#x02009;&#x000b1;&#x02009;132.8&#x02009;&#x000b5;mol/L and LC&#x02010;HGI 262.7&#x02009;&#x000b1;&#x02009;138.1&#x02009;&#x000b5;mol/L), while ketone bodies on day 15 were significantly higher in the LC&#x02010;HGI group compared with the HC&#x02010;HGI and HC&#x02010;LGI groups (day 15: HC&#x02010;HGI 502.9&#x02009;&#x000b1;&#x02009;365.2&#x02009;&#x000b5;mol/L, HC&#x02010;LGI 360.9&#x02009;&#x000b1;&#x02009;184.7&#x02009;&#x000b5;mol/L and LC&#x02010;HGI 752.4&#x02009;&#x000b1;&#x02009;249.2&#x02009;&#x000b5;mol/L [Figure S4]). Other variables are shown in Figures S4 to S7.</p><p id="dom12848-para-0019">All adverse events were mild in severity (Table S1). Among them, somnolence and urinary frequency were judged as adverse drug reactions; dermatitis was attributable to contact with fixed tape for CGM.</p></sec><sec id="dom12848-sec-0008"><label>4</label><title>DISCUSSION</title><p id="dom12848-para-0020">In the present study, we found that luseogliflozin ameliorated hyperglycaemia in Japanese people with T2D receiving the 3 different test meals; however, ketone bodies were significantly increased by luseogliflozin in the LC&#x02010;HGI group.</p><p id="dom12848-para-0021">Luseogliflozin improved AUC<sub>0&#x02010;48h</sub> and mean of CGM data in all 3 groups, indicating that differences in carbohydrate content (55% vs 40% of TEC) and GI (white rice vs brown rice) did not affect the glucose&#x02010;lowering effects. Luseogliflozin did not affect SD or MAGE values, confirming that SGLT2 inhibitors improve glycaemia without affecting glucose variability.<xref rid="dom12848-bib-0014" ref-type="ref">14</xref>
</p><p id="dom12848-para-0022">Luseogliflozin significantly increased ketone bodies in the LC&#x02010;HGI group compared with the HC&#x02010;HGI and HC&#x02010;HGI groups, suggesting that reducing carbohydrate content substantially, together with SGLT2 inhibitor therapy, could trigger euglycaemic DKA. While the euglycaemic DKA cases reported in the USA were mostly in insulin&#x02010;dependent T1D,<xref rid="dom12848-bib-0004" ref-type="ref">4</xref>, <xref rid="dom12848-bib-0005" ref-type="ref">5</xref> a number of euglycaemic DKA cases have been reported in Japanese people with T2D receiving SGLT2 inhibitors.<xref rid="dom12848-bib-0006" ref-type="ref">6</xref> This difference might be attributable to the fact that T2D in East&#x02010;Asian populations, including Japanese populations, is characterized primarily by &#x003b2;&#x02010;cell dysfunction rather than insulin resistance and subsequent hyperinsulinaemia. Indeed, many euglycaemic DKA cases in Japanese people with T2D receiving SGLT2 inhibitors occurred after withdrawal of sulphonylureas and/or insulin.<xref rid="dom12848-bib-0006" ref-type="ref">6</xref> The present study showed that ketone bodies were significantly increased by luseogliflozin in the LC&#x02010;HGI group, suggesting that SGLT2 inhibitors might trigger onset of euglycaemic DKA in individuals on a strict LC diet, with or without withdrawal of insulin and/or sulphonylureas.</p><p id="dom12848-para-0023">Limitations of the present study include the lack of UGE measurements because of difficulties in 24&#x02010;hour urine collection for outpatient participants; however, it is of interest to investigate the effects of carbohydrate intake adjustments on UGE before and after SGLT2 inhibitor treatment. UGE occurs when plasma glucose levels are higher than the renal threshold and SGLT2 inhibitor treatment lowers the threshold.<xref rid="dom12848-bib-0015" ref-type="ref">15</xref> Because glucose profiles of the HC&#x02010;LGI and LC&#x02010;HGI groups were similar and lower than in the HC&#x02010;HGI group before and after luseogliflozin treatment in the present study (Figure S3 and Table <xref rid="dom12848-tbl-0002" ref-type="table-wrap">2</xref>), the UGEs in the HC&#x02010;LGI and LC&#x02010;HGI groups might well be similar and lower than in the HC&#x02010;HGI group.</p><p id="dom12848-para-0024">It is also uncertain whether 1&#x02009;week is sufficient to stabilize the effects of dietary interventions in the absence or presence of luseogliflozin; it was previously shown that inter&#x02010;day variability of daily glucose profiles over 3 consecutive days was minimal (mean of daily difference [MODD] 1.3&#x02010;1.6&#x02009;mmol/L) when food consumption was tightly controlled,<xref rid="dom12848-bib-0016" ref-type="ref">16</xref> as it was in the present study (MODD 0.9&#x02010;1.3&#x02009;mmol/L); however, the effects during days 8 to 15 might partly be derived from the combined action of luseogliflozin and the dietary interventions.</p><p id="dom12848-para-0025">In addition, the present study compared the effects of SGLT2 inhibitor use and carbohydrate intake adjustments for a short duration with a relatively small sample size; further investigations are necessary to address long&#x02010;term safety and efficacy of SGLT2 inhibitors in individuals receiving meals of various carbohydrate content.</p><p id="dom12848-para-0026">In conclusion, the present study shows the glucose&#x02010;lowering effects of luseogliflozin, typical of SGLT2 inhibitors, with limited adverse events in Japanese people with T2D receiving meals consisting of 40% to 55% TEC with either an HGI or a LGI; however, our results suggest that the carbohydrate content of meals can play an important role in SGLT2 inhibitor&#x02010;associated hepatic ketogenesis and onset of euglycaemic DKA.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12848-supitem-0001"><caption><p>
<bold>Appendix S1.</bold> Test meals and continuous glucose monitoring.</p></caption><media xlink:href="DOM-19-739-s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12848-supitem-0002"><caption><p id="dom12848-para-0001">
<bold>Figure</bold>
<styled-content style="fixed-case"><bold>S1</bold></styled-content>
<bold>.</bold> The <styled-content style="fixed-case">CONSORT F</styled-content>low diagram of the study.</p><p id="dom12848-para-0002">
<bold>Figure</bold>
<styled-content style="fixed-case"><bold>S2</bold></styled-content>
<bold>.</bold> Design of the study.</p><p id="dom12848-para-0003">
<bold>Figure</bold>
<styled-content style="fixed-case"><bold>S3</bold></styled-content>
<bold>.</bold> Changes of continuous glucose monitoring values.</p><p id="dom12848-para-0004">
<bold>Figure</bold>
<styled-content style="fixed-case"><bold>S4</bold></styled-content>
<bold>.</bold> Changes of fasting plasma glucose, insulin, <styled-content style="fixed-case">C</styled-content>&#x02010;peptide, glucagon, ketone bodies and non&#x02010;esterified fatty acid.</p><p id="dom12848-para-0005">
<bold>Figure</bold>
<styled-content style="fixed-case"><bold>S5</bold></styled-content>
<bold>.</bold> Changes of <styled-content style="fixed-case">SUIT</styled-content>, <styled-content style="fixed-case">HOMA</styled-content>&#x02010;&#x003b2;, <styled-content style="fixed-case">HOMA&#x02010;IR</styled-content> and <styled-content style="fixed-case">G</styled-content>lucagon/<styled-content style="fixed-case">I</styled-content>nsulin ratio.</p><p id="dom12848-para-0006">
<bold>Figure</bold>
<styled-content style="fixed-case"><bold>S6</bold></styled-content>
<bold>.</bold> Changes of <styled-content style="fixed-case">HbA1c</styled-content>, blood pressures and serum lipids.</p><p id="dom12848-para-0007">
<bold>Figure</bold>
<styled-content style="fixed-case"><bold>S7</bold></styled-content>
<bold>.</bold> Changes of liver enzymes.</p></caption><media xlink:href="DOM-19-739-s001.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12848-supitem-0003"><caption><p>
<bold>Table S1.</bold> Summary of adverse events in the safety populations.</p></caption><media xlink:href="DOM-19-739-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12848-sec-0009"><title>ACKNOWLEDGMENTS</title><p id="dom12848-para-0027">The authors are grateful to Yoko Shigefuku of Kansai Electric Power Medical Research Institute and Michiko Yamane of Kansai Electric Power Hospital for secretarial assistance.</p><sec id="dom12848-sec-0010"><title>Conflict of interest</title><p id="dom12848-para-0028">D. Y. has received consulting and/or speaker fees from MSD KK, Novo Nordisk Pharma Ltd, Takeda Pharmaceutical Co. Ltd and Taisho Toyama Pharmaceutical Co. Ltd, and has also received clinical commissioned/joint research grants from Nippon Boehringer Ingelheim Co., Ltd, Eli Lilly and Company, Taisho Toyama Pharmaceutical Co. Ltd, MSD KK, Ono Pharmaceutical Co. Ltd, Novo Nordisk Pharma Ltd, Arklay Co. Ltd and Takeda Pharmaceutical Co. Ltd. Y. H. has received consulting and/or speaker fees from Novo Nordisk Pharma Ltd. T. K. has received consulting and/or speaker fees from Sanofi KK and has also received clinical commissioned/joint research grants from the Japan vascular disease research foundation. Y. S. has received consulting and/or speaker fees from Eli Lilly Japan KK, Sanofi KK, Novo Nordisk Pharma Inc., Glaxo&#x02010;Smith&#x02010;Kline, Taisho Pharmaceutical Co., Ltd, Taisho Toyama Pharmaceutical Co., Ltd, Astellas Pharma Inc., BD, Nippon Boehringer Ingelheim Co., Ltd, Johnson &#x00026; Johnson and Takeda Pharmaceutical Co. Ltd, and has also received clinical commissioned/joint research grants from Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly and Co., Taisho Toyama Pharmaceutical Co. Ltd, MSD KK, Ono Pharmaceutical Co. Ltd, Novo Nordisk Pharma Ltd and Arklay Co. Ltd. M. I., H. K., T. H., K. S., H. Y. and S. K. have no conflict of interest relevant to this study to report.</p></sec><sec id="dom12848-sec-0011"><title>Author contributions</title><p id="dom12848-para-0029">D. Y., M. I. and Y. S. contributed to conception and design of the research and analysis and interpretation of data and writing of the manuscript. S. K. contributed to design of the research, collection of data and revision of the manuscript critically for important intellectual content. K. S. and H. Y. contributed to statistical analysis and interpretation of data and writing of the manuscript. H. K., T. H., Y. H. and T. K. contributed to analysis and interpretation of data and revision of the manuscript critically for important intellectual content. All the authors approved the version to be published. D. Y. and Y. S. are the guarantors of this work.</p></sec></ack><ref-list content-type="cited-references" id="dom12848-bibl-0001"><title>REFERENCES</title><ref id="dom12848-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12848-cit-0001">
<string-name>
<surname>Fujita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Inagaki</surname>
<given-names>N</given-names>
</string-name>. <article-title>Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action</article-title>. <source>J Diabetes Invest</source>. <year>2014</year>;<volume>5</volume>:<fpage>265</fpage>&#x02010;<lpage>275</lpage>.</mixed-citation></ref><ref id="dom12848-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12848-cit-0002">
<string-name>
<surname>Hasan</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Alsahli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gerich</surname>
<given-names>JE</given-names>
</string-name>. <article-title>SGLT2 inhibitors in the treatment of type 2 diabetes</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2014</year>;<volume>104</volume>:<fpage>297</fpage>&#x02010;<lpage>322</lpage>.<pub-id pub-id-type="pmid">24735709</pub-id></mixed-citation></ref><ref id="dom12848-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12848-cit-0003">
<string-name>
<surname>Yabe</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Nishikino</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kaneko</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Iwasaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Short&#x02010;term impacts of sodium/glucose co&#x02010;transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events</article-title>. <source>Expert Opin Drug Saf</source>. <year>2015</year>;<volume>14</volume>:<fpage>795</fpage>&#x02010;<lpage>800</lpage>.<pub-id pub-id-type="pmid">25851664</pub-id></mixed-citation></ref><ref id="dom12848-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12848-cit-0004">
<string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ferrannini</surname>
<given-names>E</given-names>
</string-name>. <article-title>Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors</article-title>. <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>:<fpage>1638</fpage>&#x02010;<lpage>1642</lpage>.<pub-id pub-id-type="pmid">26294774</pub-id></mixed-citation></ref><ref id="dom12848-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12848-cit-0005">
<string-name>
<surname>Taylor</surname>
<given-names>SI</given-names>
</string-name>, <string-name>
<surname>Blau</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Rother</surname>
<given-names>KI</given-names>
</string-name>. <article-title>SGLT2 inhibitors may predispose to ketoacidosis</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2015</year>;<volume>100</volume>:<fpage>2849</fpage>&#x02010;<lpage>2852</lpage>.<pub-id pub-id-type="pmid">26086329</pub-id></mixed-citation></ref><ref id="dom12848-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12848-cit-0006">
<string-name>
<surname>Ogawa</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Sakaguchi</surname>
<given-names>K</given-names>
</string-name>. <article-title>Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors</article-title>. <source>J Diabetes Invest</source>. <year>2016</year>;<volume>7</volume>:<fpage>135</fpage>&#x02010;<lpage>138</lpage>.</mixed-citation></ref><ref id="dom12848-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12848-cit-0007">
<string-name>
<surname>Hayami</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kamiya</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Case of ketoacidosis by a sodium&#x02010;glucose cotransporter 2 inhibitor in a diabetic patient with a low&#x02010;carbohydrate diet</article-title>. <source>J Diabetes Invest</source>. <year>2015</year>;<volume>6</volume>:<fpage>587</fpage>&#x02010;<lpage>590</lpage>.</mixed-citation></ref><ref id="dom12848-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12848-cit-0008">
<article-title>American Diabetes Association. Standards of medical care in diabetes&#x02010;2016</article-title>. <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>(<issue>suppl 1</issue>):<fpage>S25</fpage>&#x02010;<lpage>S28</lpage>.</mixed-citation></ref><ref id="dom12848-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12848-cit-0009">
<string-name>
<surname>Tajima</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Noda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Origasa</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Evidence&#x02010;based practice guideline for the treatment for diabetes in Japan 2013</article-title>. <source>Diabetol Int</source>. <year>2015</year>;<volume>6</volume>:<fpage>151</fpage>&#x02010;<lpage>187</lpage>.</mixed-citation></ref><ref id="dom12848-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12848-cit-0010">
<string-name>
<surname>Sasaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukatsu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ubukata</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sakai</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Samukawa</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Pharmacokinetics, pharmacodynamics, and safety of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, single&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>Adv Ther</source>. <year>2015</year>;<volume>32</volume>:<fpage>319</fpage>&#x02010;<lpage>340</lpage>.<pub-id pub-id-type="pmid">25855342</pub-id></mixed-citation></ref><ref id="dom12848-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12848-cit-0011">
<string-name>
<surname>McDonnell</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Donath</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Vidmar</surname>
<given-names>SI</given-names>
</string-name>, <string-name>
<surname>Werther</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Cameron</surname>
<given-names>FJ</given-names>
</string-name>. <article-title>A novel approach to continuous glucose analysis utilizing glycemic variation</article-title>. <source>Diabetes Technol Ther</source>. <year>2005</year>;<volume>7</volume>:<fpage>253</fpage>&#x02010;<lpage>263</lpage>.<pub-id pub-id-type="pmid">15857227</pub-id></mixed-citation></ref><ref id="dom12848-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12848-cit-0012">
<string-name>
<surname>Ferrannini</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Muscelli</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Frascerra</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Metabolic response to sodium&#x02010;glucose cotransporter 2 inhibition in type 2 diabetic patients</article-title>. <source>J Clin Invest</source>. <year>2014</year>;<volume>124</volume>:<fpage>499</fpage>&#x02010;<lpage>508</lpage>.<pub-id pub-id-type="pmid">24463454</pub-id></mixed-citation></ref><ref id="dom12848-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12848-cit-0013">
<string-name>
<surname>Merovci</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Solis&#x02010;Herrera</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Daniele</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production</article-title>. <source>J Clin Invest</source>. <year>2014</year>;<volume>124</volume>:<fpage>509</fpage>&#x02010;<lpage>514</lpage>.<pub-id pub-id-type="pmid">24463448</pub-id></mixed-citation></ref><ref id="dom12848-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12848-cit-0014">
<string-name>
<surname>Nishimura</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Osonoi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kanada</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Effects of luseogliflozin, a sodium&#x02010;glucose co&#x02010;transporter 2 inhibitor, on 24&#x02010;h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double&#x02010;blind, placebo&#x02010;controlled, crossover study</article-title>. <source>Diabetes Obes Metab</source>. <year>2015</year>;<volume>17</volume>:<fpage>800</fpage>&#x02010;<lpage>804</lpage>.<pub-id pub-id-type="pmid">25930989</pub-id></mixed-citation></ref><ref id="dom12848-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12848-cit-0015">
<string-name>
<surname>DeFronzo</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Hompesch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kasichayanula</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2013</year>;<volume>36</volume>:<fpage>3169</fpage>&#x02010;<lpage>3176</lpage>.<pub-id pub-id-type="pmid">23735727</pub-id></mixed-citation></ref><ref id="dom12848-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12848-cit-0016">
<string-name>
<surname>Pearce</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Noakes</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Keogh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Clifton</surname>
<given-names>PM</given-names>
</string-name>. <article-title>Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes</article-title>. <source>Am J Clin Nutr</source>. <year>2008</year>;<volume>87</volume>:<fpage>638</fpage>&#x02010;<lpage>644</lpage>.<pub-id pub-id-type="pmid">18326602</pub-id></mixed-citation></ref></ref-list></back></article>